# CHRS catalysts: Coherus Oncology, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/chrs/catalysts

> Coherus Oncology, Inc. (CHRS) has 3 upcoming catalysts. The next is the MVASI® (bevacizumab) topline data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CHRS?

Coherus Oncology, Inc. (CHRS) has 3 upcoming catalysts. The next is the MVASI® (bevacizumab) topline data readout, 1H 2027. Press release filed with the SEC (EX-99): "Enrollment in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC is complete and the first data readout is expected in 1H 2027." [Calendar and source filings](https://sec-api.dev/companies/chrs/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-124511, https://www.sec.gov/Archives/edgar/data/1512762/000110465926124511/chrs-ex99d1.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/companies/chrs/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Coherus Oncology, Inc. |
| Ticker | CHRS (Nasdaq) |
| SEC CIK | 1512762 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/chrs |

## Cash runway

Cash $83.6M as of 2026-09-30; quarterly burn $34.0M; about 7.4 months of runway at that rate (XBRL company facts, accession 0001104659-26-124572).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 9, 2017 | [Udenyca (pegfilgrastim-cbqv) complete response letter (CRL)](https://sec-api.dev/pdufa/pegfilgrastim-cbqv) | CHRS |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761039_2018_Orig1s000OtherActionLtrs.pdf%22)) |
| November 2, 2018 | [Udenyca (pegfilgrastim-cbqv) FDA approval](https://sec-api.dev/pdufa/pegfilgrastim-cbqv) | CHRS |  | completed, approved | "BLA761039 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20181102, review_priority STANDARD; sponsor_name COHERUS BIOSCIENCES INC; product UDENYCA (PEGFILGRASTIM-CBQV)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761039%22)) |
| April 29, 2022 | [Loqtorzi (toripalimab-tpzi) complete response letter (CRL)](https://sec-api.dev/pdufa/toripalimab-tpzi) | CHRS |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761240_2023_Orig1s000OtherActionLtrs.pdf%22)) |
| August 2, 2022 | [Lucentis® (ranibizumab) FDA approval](https://sec-api.dev/pdufa/ranibizumab) | CHRS | neovascular | completed, approved | "CIMERLI (ranibizumab-eqrn), a Lucentis biosimilar, was approved by the FDA on August 2, 2022 for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization and we launched CIMERLI commercially in the United States on October 3, 2022." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465925111484/chrs-20251113xex99d1.htm)) |
| August 2, 2022 | [Biosimilar FDA approval](https://sec-api.dev/pdufa/biosimilar) | CHRS | neovascular | completed, approved | "CIMERLI (ranibizumab-eqrn), a Lucentis biosimilar, was approved by the FDA on August 2, 2022 for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization and we launched CIMERLI commercially in the United States on October 3, 2022." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1512762/000155837025003126/chrs-20241231x10k.htm)) |
| August 2, 2022 | [CIMERLI (cimerli) FDA approval](https://sec-api.dev/pdufa/cimerli) | CHRS |  | completed, approved | "On August 2, 2022, the FDA approved CIMERLI, which we launched in the United States in October 2022." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1512762/000155837025003126/chrs-20241231x10k.htm)) |
| November 28, 2022 | [Udenyca (pegfilgrastim-cbqv) label expansion decision](https://sec-api.dev/pdufa/pegfilgrastim-cbqv) | CHRS |  | completed, approved | "BLA761039 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20221128, review_priority STANDARD; sponsor_name COHERUS BIOSCIENCES INC; product UDENYCA (PEGFILGRASTIM-CBQV)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761039%22)) |
| March 3, 2023 | [Udenyca (pegfilgrastim-cbqv) label expansion decision](https://sec-api.dev/pdufa/pegfilgrastim-cbqv) | CHRS |  | completed, approved | "BLA761039 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20230303, review_priority STANDARD; sponsor_name COHERUS BIOSCIENCES INC; product UDENYCA (PEGFILGRASTIM-CBQV)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761039%22)) |
| Jul 2023 | [YUSIMRY (yusimry) FDA approval](https://sec-api.dev/pdufa/yusimry) | CHRS |  | completed, approved | "In December 2021, the FDA approved YUSIMRY, which we launched in the United States in July 2023." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465925111484/chrs-20251113xex99d1.htm)) |
| October 27, 2023 | [LOQTORZI (toripalimab) FDA approval](https://sec-api.dev/pdufa/toripalimab) | CHRS | with recurrent, unresectable, or metastatic NPC with disease progression | completed, approved | "On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465925111484/chrs-20251113xex99d1.htm)) |
| October 27, 2023 | [Loqtorzi (toripalimab-tpzi) FDA approval](https://sec-api.dev/pdufa/toripalimab-tpzi) | CHRS |  | completed, approved | "Loqtorzi \| toripalimab-tpzi \| 10/27/2023 \| To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| December 22, 2023 | [Udenyca (pegfilgrastim-cbqv) label expansion decision](https://sec-api.dev/pdufa/pegfilgrastim-cbqv) | CHRS |  | completed, approved | "BLA761039 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20231222, review_priority STANDARD; sponsor_name COHERUS BIOSCIENCES INC; product UDENYCA (PEGFILGRASTIM-CBQV)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761039%22)) |
| Jan 2024 | [LOQTORZI (toripalimab) FDA approval](https://sec-api.dev/pdufa/toripalimab) | CHRS |  | completed, approved | "Following the FDA approval of LOQTORZI for NPC, the commercial launch commenced in January 2024 with our existing Oncology commercial and medical affairs teams." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1512762/000155837025003126/chrs-20241231x10k.htm)) |
| March 10, 2025 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000155837025002595/chrs-20250310xex99d1.htm)) |
| May 12, 2025 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000155837025007410/chrs-20250512xex99d1.htm)) |
| June 30, 2025 | [Casdozokitug primary completion](https://sec-api.dev/pdufa/casdozokitug) | CHRS | Hepatocellular Carcinoma | withdrawn | "NCT05359861 (Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor Coherus Oncology, Inc.; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05359861)) |
| August 7, 2025 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000155837025010802/chrs-20250807xex99d1.htm)) |
| November 6, 2025 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465925107780/chrs-20251106xex99d1.htm)) |
| March 9, 2026 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/chrs-20260309xex99d1.htm)) |
| mid-2026 | [LOQTORZI (toripalimab) interim data readout](https://sec-api.dev/pdufa/toripalimab) | CHRS |  | scheduled | "The Phase 1b tagmokitug/toripalimab combination dose optimization studies in 2L HNSCC and 2L upper GI adenocarcinoma cancers are underway, with initial data readouts expected in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/chrs-20260511xex99d1.htm)) |
| Q2 2026 | [LOQTORZI (toripalimab) topline data readout](https://sec-api.dev/pdufa/toripalimab) | CHRS |  | scheduled | "The Company initiated a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L HNSCC in Q1 2025 with a first data readout expected in Q2 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000155837025007410/chrs-20250512xex99d1.htm)) |
| May 11, 2026 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/chrs-20260511xex99d1.htm)) |
| 2H 2026 | [LOQTORZI (toripalimab) topline data readout](https://sec-api.dev/pdufa/toripalimab) | CHRS |  | scheduled | "A Phase 1b study evaluating the tagmokitug/toripalimab combination, with and without chemotherapy, in 1L and 2L esophageal squamous cell carcinoma (ESCC), respectively, is underway with a first data readout expected in 2H 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/chrs-20260511xex99d1.htm)) |
| 2H 2026 | [MVASI® (bevacizumab) topline data readout](https://sec-api.dev/pdufa/bevacizumab) | CHRS |  | scheduled | "Enrollment is complete in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC and the first data readout is expected 2H 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/chrs-20260805xex99d1.htm)) |
| 2H 2026 | [Tagmokitug interim data readout](https://sec-api.dev/pdufa/tagmokitug) | CHRS |  | scheduled | "The Phase 1b dose-optimization studies evaluating tagmokitug in combination with toripalimab in second-line head and neck squamous cell carcinoma (HNSCC) and upper gastrointestinal adenocarcinomas remain ongoing, with initial data readouts expected in 2H 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/chrs-20260805xex99d1.htm)) |
| August 5, 2026 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/chrs-20260805xex99d1.htm)) |
| November 9, 2026 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465926124511/chrs-ex99d1.htm)) |
| 1H 2027 | [MVASI® (bevacizumab) topline data readout](https://sec-api.dev/pdufa/bevacizumab) | CHRS |  | scheduled | "Enrollment in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC is complete and the first data readout is expected in 1H 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465926124511/chrs-ex99d1.htm)) |
| September 2027 | [Casdozokitug primary completion](https://sec-api.dev/pdufa/casdozokitug) | CHRS | Hepatocellular Carcinoma | scheduled | "NCT06679985 (A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Coherus Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06679985)) |
| Sep to Dec 2027 | [Casdozokitug topline data readout](https://sec-api.dev/pdufa/casdozokitug) | CHRS | Hepatocellular Carcinoma | scheduled | "NCT06679985 (A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Coherus Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06679985)) |

## Drugs

- [Casdozokitug](https://sec-api.dev/pdufa/casdozokitug): Hepatocellular Carcinoma
- [CIMERLI (cimerli)](https://sec-api.dev/pdufa/cimerli): 
- [Udenyca (pegfilgrastim-cbqv)](https://sec-api.dev/pdufa/pegfilgrastim-cbqv): 
- [Tagmokitug](https://sec-api.dev/pdufa/tagmokitug): 
- [LOQTORZI (toripalimab)](https://sec-api.dev/pdufa/toripalimab): with recurrent, unresectable, or metastatic npc with disease progression, with recurrent unresectable, or metastatic npc with disease progression, with recurrent, unresectable, or metastatic npc with disease
- [Loqtorzi (toripalimab-tpzi)](https://sec-api.dev/pdufa/toripalimab-tpzi): 
- [YUSIMRY (yusimry)](https://sec-api.dev/pdufa/yusimry): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/chrs/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CHRS catalysts: Coherus Oncology, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/chrs/catalysts

```bibtex
@misc{secapidev_companies_chrs_catalysts_20261116,
  title        = {CHRS catalysts: Coherus Oncology, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/chrs/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_chrs_catalysts_20261116","title":"CHRS catalysts: Coherus Oncology, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/chrs/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
